- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALERISLIFE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 49,700 | -0,64 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 44,000 | +0,23 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Carl Zeiss Meditec mit einem Kursziel von 35,10 Euro auf "Underweight" belassen. Vor den am 11. Dezember anstehenden Quartalszahlen lägen seine... ► Artikel lesen | |
| M1 KLINIKEN | 15,820 | -0,38 % | M1 Kliniken-Tochter Hameato verkauft Pharmasparte an Phoenix | Die M1 Kliniken AG hat mitgeteilt, dass ihre 85-Prozent-Beteiligung Hameato AG die 100-Prozent-Tochtergesellschaft Hameato Pharm GmbH an die Phoenix group verkauft hat. Zu den finanziellen Details machten... ► Artikel lesen | |
| DEXCOM | 50,85 | +0,22 % | DexCom Inc. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - DexCom Inc. (DXCM) reported earnings for its third quarter that Increased from last year and beat the Street estimates.The company's bottom line came in at $283.8 million... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,534 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights | US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct.... ► Artikel lesen | |
| CARDINAL HEALTH | 166,00 | +0,27 % | Cardinal Health, Inc.: Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook | Revenue increased 22% to $64 billion
GAAP 1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88
Non-GAAP operating... ► Artikel lesen | |
| DAVITA | 102,35 | -0,78 % | DaVita Inc. 3rd Quarter 2025 Results | DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025.
"Our third quarter... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Announces Voting Results from Special Meeting of Stockholders / Evofem Shareholders Did Not Approve the Merger with Aditxt | -- Evofem Shareholders Did Not Approve the Merger with Aditxt --
-- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales... ► Artikel lesen | |
| DENTSPLY SIRONA | 11,005 | +0,55 % | DENTSPLY SIRONA Inc.: Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization | CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President... ► Artikel lesen | |
| CENTENE | 30,850 | +0,69 % | Centene Corporation Reports Third Quarter 2025 Results | -- GAAP Diluted Loss Per Share of $(13.50); Adjusted Diluted Earnings Per Share of $0.50 --
Adjusted diluted EPS of $0.50 in the third quarter of 2025, including... ► Artikel lesen | |
| CYTOSORBENTS | 0,663 | -0,15 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
| COOPER COMPANIES | 61,00 | 0,00 % | What to Expect From Cooper Companies' Next Quarterly Earnings Report | ||
| EKSO BIONICS | 5,365 | 0,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Third Quarter 2025 Financial Results | SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| FULGENT GENETICS | 19,400 | -1,02 % | Fulgent Genetics meldet positive Studiendaten bei Kopf- und Halskrebs | ||
| IMUNON | 4,100 | +3,02 % | Imunon, Inc.: IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement | LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company... ► Artikel lesen |
ALERISLIFE INC gehört der Branche Gesundheitswesen an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALERISLIFE INC finden Sie auf Wallstreet Online.